Des-Gamma-Carboxy Prothrombin (DCP) Antagonizes the Effects of Gefitinib on Human Hepatocellular Carcinoma Cells | Zendy

Yusheng Zhang | Zendy; Jiahui Chu | Zendy; Zhiyu Song | Zendy; ShuXiang Cui | Zendy; XianJun Qu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Des-Gamma-Carboxy Prothrombin (DCP) Antagonizes the Effects of Gefitinib on Human Hepatocellular Carcinoma Cells

Author(s) -

Yusheng Zhang,

Jiahui Chu,

Zhiyu Song,

ShuXiang Cui,

XianJun Qu

Publication year - 2015

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000369688

Subject(s) - gefitinib , apoptosis , cancer research , epidermal growth factor receptor , annexin , cell growth , hepatocellular carcinoma , signal transduction , cell culture , epidermal growth factor , chemistry , medicine , biology , receptor , microbiology and biotechnology , biochemistry , genetics

Des-gamma-carboxy prothrombin (DCP), an aberrant prothrombin produced by hepatocellular carcinoma (HCC) cells, is known as a marker for HCC. Recent studies indicated that high levels of DCP are associated with the malignant potential of HCC. In this study, we aimed to investigate the association of DCP with gefitinib treatment failure in HCC and whether DCP counteracts gefitinib-induced growth inhibition and apoptosis of HCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research